Bristol Myers Squibb (BMY) Brings First FDA Approved CELMoD to Multiple Myeloma Patients

Simply Wall St.11-05 21:32

Bristol-Myers Squibb (NYSE:BMY) has selected Polaris Rx to dispense ZENBEXUS (iberdomide), the first FDA-approved CELMoD for multiple myeloma. The appointment of Polaris Rx positions the pharmacy to ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2681079356?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/company-cover/25798-card/1789118977455","is_english":true,"pubTime":"2026-11-05 21:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2681079356","market":"sg","top_or_hot":-1,"title":"Bristol Myers Squibb (BMY) Brings First FDA Approved CELMoD to Multiple Myeloma Patients","media":"Simply Wall St.","content":"<div>\n<p>Bristol-Myers Squibb (NYSE:BMY) has selected Polaris Rx to dispense ZENBEXUS (iberdomide), the first FDA-approved CELMoD for multiple myeloma. The appointment of Polaris Rx positions the pharmacy to ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bmy/bristol-myers-squibb/news/bristol-myers-squibb-bmy-brings-first-fda-approved-celmod-to\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers Squibb (BMY) Brings First FDA Approved CELMoD to Multiple Myeloma Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers Squibb (BMY) Brings First FDA Approved CELMoD to Multiple Myeloma Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-05 21:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bmy/bristol-myers-squibb/news/bristol-myers-squibb-bmy-brings-first-fda-approved-celmod-to><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bristol-Myers Squibb (NYSE:BMY) has selected Polaris Rx to dispense ZENBEXUS (iberdomide), the first FDA-approved CELMoD for multiple myeloma. The appointment of Polaris Rx positions the pharmacy to ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bmy/bristol-myers-squibb/news/bristol-myers-squibb-bmy-brings-first-fda-approved-celmod-to\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK6514","symbol_name":"零售商股","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bmy/bristol-myers-squibb/news/bristol-myers-squibb-bmy-brings-first-fda-approved-celmod-to","article_id":"2681079356","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/company-cover/25798-card/1789118977455"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bmy/bristol-myers-squibb/news/bristol-myers-squibb-bmy-brings-first-fda-approved-celmod-to","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2681079356","pubTimestamp":1793885573,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"BBailey PembertonNovember 5, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK6514":"零售商股","BK4532":"文艺复兴科技持仓","BK4581":"高盛持仓","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","IHE":"iShares U.S. Pharmaceuticals ETF","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","BK4585":"ETF&股票定投概念","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","BK4534":"瑞士信贷持仓","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","FTXH":"First Trust Nasdaq Pharmaceuticals ETF","LU0882574055.USD":"富达全球健康医疗A ACC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU1236620750.USD":"HSBC GIF GLOBAL SUSTAINABLE LONG TERM DIVIDEND \"AM2\" (USD) INC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1236620834.HKD":"HSBC GIF GLOBAL SUSTAINABLE LONG TERM DIVIDEND \"AM2\" (HKD) INC","BK4559":"巴菲特持仓","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0058720904.USD":"联博国际健康护理基金A","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4588":"碎股","LABU":"三倍做多标普生物-Direxion","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BMY":"施贵宝","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","5BI.SI":"POLARIS公司","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC"},"translate_title":"百时美施贵宝 (BMY) 为多发性骨髓瘤患者带来首个 FDA 批准的 CELMoD","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"IHE":0.6,"FTXH":0.6,"5BI.SI":0.73,"BMY":1.5},"content_text":"Bristol-Myers Squibb (NYSE:BMY) has selected Polaris Rx to dispense ZENBEXUS (iberdomide), the first FDA-approved CELMoD for multiple myeloma. The appointment of Polaris Rx positions the pharmacy to handle prescriptions and patient access services for ZENBEXUS across eligible multiple myeloma patients. This dispensing role ties Polaris Rx directly into Bristol Myers Squibb's broader hematology portfolio centered on CELMoD therapies. The choice of Polaris Rx for ZENBEXUS distribution is part of a wider pattern in Bristol Myers Squibb's hematology strategy that our research tracks. We have also flagged 3 warning signs (1 major) for Bristol-Myers Squibb.  For readers watching how new therapies and specialty distributors intersect with broader drug development and AI infrastructure, there is a wider set of stocks worth comparing through 53 AI infrastructure stocks. NYSE:BMY Earnings & Revenue Growth as at Nov 2026 Bristol-Myers Squibb is a US biopharmaceutical group with a US$126.1b market cap that discovers, develops, licenses, manufactures, and distributes prescription drugs. Adding a first-in-class CELMoD therapy for multiple myeloma aligns directly with its focus on specialized oncology treatments. 4 things going right for Bristol-Myers Squibb that this headline doesn't cover. AdvertisementZENBEXUS and Polaris Rx show Bristol-Myers Squibb pushing its growth-portfolio narrative into practice The Bristol-Myers Squibb Narrative rests on a simple bet that growth-portfolio oncology and hematology drugs can increasingly offset pressure on older blockbusters, supported by focused partnerships and disciplined execution. Routing ZENBEXUS through Polaris Rx plugs an approved CELMoD into that story by tying a new therapy to a controlled, specialist distribution channel.  \"Progress in next generation oncology assets, including filed and accepted NDAs for iberdomide and mezigdomide and strong registrational data for arlo cel, points to potential new multiple myeloma and hematology contributors that can add to long term revenue and help replace expiring therapies...\"  See how the full story points towards a $65.25 fair value for Bristol-Myers Squibb. This move pushes the iberdomide part of the Bristol-Myers Squibb thesis out of the clinical realm and into commercial execution. The partnership with Polaris Rx directly supports the Narrative’s focus on turning CELMoD trial work into real-world use, at a time when analysts are watching how quickly newer oncology products can shoulder more of the cash-flow load versus expiring therapies from rivals like Johnson & Johnson and Merck. At the same time, concentrating ZENBEXUS dispensing in a specialty pharmacy highlights one of the flagged risks in the story, namely that execution and safety perceptions for a relatively narrow set of launches matter more when earnings are expected to soften over the next few years. Any friction in access, from reimbursement hurdles to distribution bottlenecks, would cut against the Narrative’s claim that partnerships and productivity can keep supporting margins and dividend-backed returns. For Bristol-Myers Squibb, this ZENBEXUS distribution news only really matters if you already buy into, or actively doubt, the broader Narrative that new hematology drugs and focused collaborations can carry the business through its patent-heavy decade. Add Bristol-Myers Squibb to your Watchlist and get alerts as these catalysts play out. This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Bristol-Myers Squibb might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2681079356","isCrawlerRequest":true}